The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19

The potential of heparin-induced extracorporeal LDL/fibrinogen precipitation (H.E.L.P.)-apheresis for patients with severe acute or chronic COVID-19

Patients with long COVID and acute COVID should benefit from treatment with H.E.L.P. apheresis, which is in clinical use for 37 years. COVID-19 can cause a severe acute multi-organ illness and, subsequently, in many patients the chronic illness long-COVID/PASC. The alveolar tissue and adjacent capil...

Full description

Bibliographic Details
Main Authors: Beate Roxane Jaeger, Hayley Emma Arron, Wiltrud M. Kalka-Moll, Dietrich Seidel
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
H.E.L.P. apheresis
PASC
COVID-19
long COVID
SARS-CoV-2
heparin
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.1007636/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.1007636/full

Similar Items